Treatment of AIDS Vacuolar Myelopathy With Methionine

Phase 3

Completed

• Conditions: Myelopathy; AIDS-Myelopathy; AIDS Vacuolar Myelopathy

• Registration Number: NCT00032695
• Lead Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Brief Summary

The purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.

Detailed Description

Myelopathy is usually a late complication of AIDS, and until recently its symptoms were rarely recognized, masked by the general state of disability or the presence of other neurological complications. With prolonged survival and improved quality of life of HIV-infected patients, myelopathy is increasingly becoming a common source of disability. The cause of AIDS-myelopathy is unknown, but it is probably an indirect effect of the long-term presence of the HIV virus in the nervous system rather than the result of a direct infection. The purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.

Study Timeline

• Study First Submitted: 2002-03-28
• Study First Submitted QC: 2002-03-28
• Study First Posted: 2002-03-29
• Status Verified: 2005-11
• Last Update Submitted: 2006-05-12
• Last Update Posted: 2006-05-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Beth Israel Medical Center; 🇺🇸 New York, New York, United States